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Objectives. The objective of this paper is to determine if hyaluronan aﬀects bupivacaine’s anesthetic function. Methods. Whole
cell patch clamp recordings were performed on bovine articular chondrocytes cultured in 60mm dishes. The chondrocytes were
treated with phosphate-buﬀered saline (control group), 7.5mg/mL hyaluronan (Orthovisc), 0.25% bupivacaine, or a mixture of
7.5mg/mL hyaluronan and 0.25% bupivacaine. Outward currents were elicited by step depolarization from −90mV to 150mV
with 5mV increments and holding for 200ms. Results. The amplitude of outward currents elicited at 150mV was 607.1±135.4pA
(mean ± standard error) in the chondrocytes treated with phosphate buﬀered saline, 550.0±194.9pA in the chondrocytes treated
with hyaluronan, 18.4±8.3pA in the chondrocytes treated with bupivacaine, and 12.8±2.6pA in the chondrocytes treated with a
mixture of hyaluronan and bupivacaine. Conclusion. Hyaluronan does not aﬀect bupivacaine’s inhibitory action on the potassium
channel activities in bovine articular chondrocytes. This ﬁnding suggests that intra-articular injection of a mixture of hyaluronan
and bupivacaine may not aﬀect the anesthetic eﬀects of bupivacaine.
1.Introduction
Bupivacaine is a local anesthetic that is an amine compound
and is commonly used after arthroscopic surgery for post-
operative pain control [1]. Bupivacaine achieves its anes-
thetic eﬀect by binding to sodium, potassium, and calcium
channelsofneuronstherebyinhibitingpropagationofaction
potentials [2, 3]. Scholz reported that the receptor for bupi-
vacaine is localized inside the channels, not on the extracel-
lular surface of them [2]. Orthovisc is a bacterially derived,
high molecular weight (1.0–2.9 million daltons) sodium hy-
aluronate dissolved in a physiologic saline solution with
a hyaluronan concentration of 15mg/mL (manufactured
by Anika Therapeutics, Inc., Woburn, Massachusetts, and
distributed by Depuy Mitek, Raynham, Massachusetts). Or-
thovisc is indicated for the treatment of arthritic pain in
human knee joints [4]. Gomis et al. proposed that the high-
ly elastoviscous hyaluronan solutions achieved their anes-
thetic eﬀect by reducing the transmission of signals to
stretch activated channels in nociceptive nerve endings [5].
This implies that hyaluronan has a diﬀerent mechanism of
anesthetic action than bupivacaine.
Several recent in vitro studies have shown that bupi-
vacaine can cause reduced chondrocyte function and even
chondrocyte death [6–8]. Some studies have shown that
intra-articular injection of bupivacaine may cause chon-
drolysis particularly when administered via intra-articular
infusion pumps [9, 10]. We have recently reported that
hyaluronan may prevent bupivacaine-induced chondrotoxi-
city in bovine articular chondrocytes exposed to bupivacaine
at supraphysiologic temperatures [11]. This ﬁnding hints
at a potential of intra-articular injection of a mixture of2 Advances in Orthopedics
bupivacaine and hyaluronan; thus bupivacaine’s toxicity may
be prevented by hyaluronan. However, it is not known
whether hyaluronan may also inhibit bupivacaine’s anes-
thetic eﬀects. Thus, we conducted this study to determine
whether hyaluronan aﬀects bupivacaine’s action on the
voltage-gated potassium channels of bovine articular chon-
drocytes using whole cell patch clamp recordings.
2.MaterialsandMethods
2.1. Cell Culture. Normal bovine articular chondrocytes
were harvested from the stiﬂe joints (equivalent to human
knee joints) of 3-week-old calves obtained from an abattoir.
The chondrocytes were cultured with Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) containing 10% fetal bovine se-
rum and 1% penicillin/streptomycin (Invitrogen, Carlsbad,
California) in a 5% CO2 humidiﬁed incubator at 37◦C. The
cells used in this study were cultured in a monolayer for less
than three weeks.
2.2. Treatment of Cells in Monolayer Culture. In order to
assess the eﬀects of bupivacaine (Hospira, Inc., Lake Forest,
Illinois) and hyaluronan (Orthovisc) on bovine articular
chondrocytes, the cells were plated in 60mm dishes at a
densityof15,000cellsperdishandincubatedat37◦Cina5%
CO2-humidiﬁed incubator prior to treatment. The medium
was siphoned oﬀ, and the monolayer cultures were rinsed
twicewith3mLofphosphatebuﬀeredsaline(PBS).Thecells
were then treated with PBS or the treatment solutions per
the protocol below at room temperature. The treated cells
were allowed to incubate at room temperature for at least
ten minutes but no longer than ninety minutes before patch
clamp recordings were completed.
The treatment groups included the following:
(1) control group: treated with PBS,
(2) bupivacaine group: treated with 0.25% bupivacaine
in PBS,
(3) hyaluronan group: treated with 50% Orthovisc in
PBS (containing 7.5mg/mL hyaluronan),
(4) Hyaluronan/bupivacaine group: treated with a com-
bination of 7.5mg/mL hyaluronan and 0.25% bupi-
vacaine.
2.3. Whole Cell Patch Clamp Recording. The following pro-
cedure was based on a recently published whole cell patch
clamp technique [12]. Patch pipettes were pulled from
thick walled 1.5mm borosilicate glass with a tip resistance
between 3 and 7MΩ on an automatic micropipette puller
(Sutter Instruments, model P-97, Novato, California). The
micropipette served as a probe with an electrode connected
to the MultiClamp 700B patch clamp ampliﬁer (Molecular
Devices, Sunnyvale, California). Live cells attached to the
culture plate were identiﬁed using light microscopy at 100x
magniﬁcation (Nikon Eclipse Microscope, Japan), and then
the patch pipette was placed approximately over the cell.
Using 400x magniﬁcation, the pipette was lowered onto the
chondrocyte cell surface, and gentle suction was applied to
create a high-resistance seal. Transient currents caused by
pipette capacitance were electronically compensated by the
circuit of the ampliﬁer. If the seal resistance reached >1GΩ,
then recordings were made. The series resistance was 7–
16MΩ,andrecordingswerediscardedif signiﬁcantincreases
(>20%) in series resistance occurred. Whole cell patch re-
cordings were then made using the MultiClamp 700B am-
pliﬁer. Inward and outward currents were recorded at mem-
brane potentials ranging from −90mV to 150mV with 5mV
steps lasting 200ms. After the recordings were made, resting
membrane potentials were read from the ampliﬁer. The data
were lowpass ﬁltered at 2kHz and digitized at rates of 5kHz
before they were stored on the computer for later analysis.
The amplitudes of the outward current (pA) were recorded
before and after drug treatment.
2.4. Statistical Methods. Each cell was recorded three times,
andﬁvecellswererecordedpertreatmentgroup(n = 5).The
meansandstandarderrors(SEs)werecomparedbetweenthe
PBS control group and each treatment group using the two-
tailed Student’s t-test. The level of signiﬁcance was set at P<
0.05.
3. Results
Patch electrodes were initially ﬁlled with a solution contain-
ing 118mM cesium methane sulfonate, 12mM cesium chlo-
ride, 0.5mM calcium chloride, 0.5mM magnesium chloride,
10mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), and 5mM ethylene glycol tetraacetic acid (EGTA),
with an osmolarity of 290 and pH of 7.3. After successfully
obtaining a seal on 5 diﬀerent chondrocytes, no inward or
outward currents were able to be elicited. This prompted
us to use a diﬀerent solution thereby allowing the study
of outward currents that were found at membrane poten-
tials from 140mV to 150mV. Patch electrodes were then
ﬁlled with a solution containing 120mM potassium glu-
conate, 10mM sodium chloride, 0.5mM magnesium chlo-
ride, 0.5mM calcium chloride, 10mM HEPES, and 5mM
EGDA, with an osmolarity of 290 and pH of 7.3. From a
holding potential of −90mV depolarized to 150mV, out-
ward currents were elicited in chondrocytes treated with
PBS (Figure 1(a)) and hyaluronan (Figure 1(b)). In contrast,
the outward currents were completely inhibited when the
chondrocytes were treated with bupivacaine (Figure 1(c))o r
a combination of bupivacaine and hyaluronan (Figure 1(d)).
In order to analyze the data quantitatively, we examined
the amplitudes of outward currents elicited at 150mV
(Figures 2(a) to 2(d)). When the cells were treated with
PBS (as control), the mean outward current was 607.1pA
(SE = 135.4) (Table 1 and Figure 2(e)). When the cells were
treated with hyaluronan, the mean outward current was
550.0pA (SE = 194.9) (Table 1 and Figure 2(e)). There was
no signiﬁcant diﬀerence in the outward currents between
the control group and hyaluronan treatment group (P =
0.816). When the cells were treated with 0.25% bupivacaine,
the mean outward current decreased to 18.4pA (SE =
8.3), which was signiﬁcantly diﬀerent from the control and
hyaluronan treatment groups (P = 0.002 and P = 0.026,Advances in Orthopedics 3
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Figure 1: Representative whole cell patch clamp recordings showing outward currents elicited by step depolarization from −90mV to
150mV with 5mV increments and holding for 200ms. Bovine articular chondrocytes were treated with PBS (a), 7.5mg/mL hyaluronan (b),
0.25% bupivacaine (c), and a mixture of 7.5mg/mL hyaluronan and 0.25% bupivacaine (d).
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Figure 2: Representative whole cell patch clamp recordings showing outward currents elicited by depolarization at 150mV with holding
for 200ms. Bovine articular chondrocytes were treated with PBS (a), 7.5mg/mL hyaluronan (b), 0.25% bupivacaine (c), and a mixture of
7.5mg/mL hyaluronan and 0.25% bupivacaine (d). (e) Means and standard errors (error bars) of the outward currents recorded in ﬁve
chondrocytes (n = 5). P values were obtained by Student’s t-test (two-tailed).
resp.) (Table 1 and Figure 2(e)). When the cells were treated
with a combination of bupivacaine and hyaluronan, the
mean outward current was 12.8pA (SE = 2.6), which
was signiﬁcantly diﬀerent from the control group (P =
0.002) (Table 1 and Figure 2(e)). There was no signiﬁcant
diﬀerence between bupivacaine alone group and hyaluro-
nan/bupivacaine combined group (P = 0.534).
To make sure that we were testing live cells in the bu-
pivacaine treated group, we examined a live cell that had
been treated with PBS and recorded a mean outward current4 Advances in Orthopedics
Table 1: Outward current (pA) elicited at 150mV in bovine articular chondrocytes.
PBS Hyaluronan Bupivacaine Hyaluronan/Bupivacaine
Cell 1 454.5 297.6 13.1 6.8
Cell 2 1083.5 446.3 51.1 14.0
Cell 3 536.1 1313.0 13.6 11.3
Cell 4 679.8 246.6 8.7 9.8
Cell 5 281.4 446.5 5.6 21.9
Mean 607.1 550.0 18.4 12.8
Standard Error 135.4 194.9 8.3 2.6
P (versus PBS) 0.816 0.002 0.002
P (versus Hyaluronan) 0.026 0.025
P (versus Bupivacaine) 0.534
200 ms
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Figure 3: Representative whole cell patch clamp recordings showing outward currents elicited at 150mV with holding for 200ms. Bovine
articular chondrocytes were treated with PBS (a), 0.25% bupivacaine for 5 minutes (b), 0.25% bupivacaine for 10 minutes (c), and cesium
(potassium channel blocker) (d).
at 150mV of 491.4pA (SE = 113.3) (Figure 3(a)). Once
the recordings were obtained, we treated the cell with
0.25% bupivacaine. Then, we took recordings at ﬁve and
ten minutes after bupivacaine treatment on the same cell
at 150mV. Five minutes after bupivacaine treatment, we
recorded a mean outward current of 190.8pA (SE = 35.4)
(Figure 3(b)); ten minutes after bupivacaine treatment, we
recorded a mean outward current of 13.1pA (SE = 2.8)
(Figure 3(c)). When we added cesium (a potassium channel
blocker) to the micropipette solution, the outward currents
were completely blocked (Figure 3(d)).
4. Discussion
We performed this study to determine if hyaluronan can
inﬂuence the anesthetic action of bupivacaine. Bupivacaine
acts on sodium, potassium, and calcium channels of neuron
cells to inhibit pain sensation. Because we could not ﬁnd a
sourceofnormalneuroncelllineanditwasdiﬃculttoisolate
any primary neurons for our study, we used bovine articular
chondrocytes. We believe that this is appropriate because
bupivacaine acts on channel proteins that are the same
in both chondrocytes and neurons. Initially, we planned
to study the eﬀects of bupivacaine on the voltage-gated
sodium channels as this is the primary mechanism of local
anesthetics with an amine group [2]. However, we were
unable to elicit any inward currents in bovine articular
chondrocytes. We were able to elicit outward currents that
were inhibited by cesium, a known potassium channel
blocker [13], suggesting that the outward currents were
caused by potassium channel activities. It has been reported
that bupivacaine can block both sodium and potassium
channels [2, 14, 15]. Therefore, our study focused on the
eﬀects of bupivacaine on potassium channel activities.
We have previously shown that bupivacaine does not
cause chondrocyte death when bovine articular chondro-
cytes were treated with bupivacaine in PBS at room temper-
ature [16]. To make sure that the chondrocyte was alive, we
ﬁrst recorded the outward currents when the cell was treated
with PBS and then switched the treatment to bupivacaine.
We observed a gradual decrease of the amplitudes of the
outward currents after the chondrocyte was treated with
bupivacaine for 5 to 10 minutes. This suggests that the de-
crease of outward currents is caused by bupivacaine’s phar-
macologic action on the potassium channels, rather than
death of the chondrocyte.
In the present study, we found that hyaluronan had no
eﬀects on the voltage-gated potassium channel activities. In
contrast, bupivacaine completely inhibited the potassium
channel activities. Moreover, hyaluronan did not increase or
decrease bupivacaine’s inhibition on the potassium channel
activities when hyaluronan was mixed with bupivacaine.
These ﬁndings suggest that hyaluronan, if mixed with bupi-
vacaine, may not aﬀect bupivacaine’s anesthetic function.
I th a sb e e nr e p o r t e di na n i m a l[ 17] and human studies
[18] that the duration of sensory nerve blockade from
bupivacaine is prolonged by addition of hyaluronan. Hassan
et al. described this extended action of the local anesthetic,Advances in Orthopedics 5
but they did not determine the exact mechanism. They
speculated that hyaluronan may bind to the local anesthetic
drug, thereby delaying the drug’s access to the channel
proteins[17].Wehavepreviouslyshownthathyaluronancan
prevent bupivacaine-induced chondrotoxicity [11]. Grishko
et al. demonstrated that chondrotoxicity is accompanied
by mitochondrial dysfunction leading to deﬁcient energy
production and cell death when the cells were exposed
to local anesthetics [19]. However, hyaluronan can pre-
vent chondrocyte death by decreasing mitochondrial DNA
damage, enhancing mitochondrial DNA repair capacity,
and preserving cellular ATP levels [20]. The ﬁndings from
the present study demonstrate that hyaluronan may not
aﬀect bupivacaine’s anesthetic function. Taken together, it
is reasonable to speculate that intra-articular injection of a
mixture of hyaluronan and bupivacaine may oﬀer adequate
pain relief and avoid potential side eﬀects caused by bupiva-
caine.
5. Conclusion
Hyaluronan does not aﬀect bupivacaine’s inhibitory action
on the potassium channel activities in bovine articular chon-
drocytes. This ﬁnding suggests that intra-articular injection
of a mixture of hyaluronan and bupivacaine may not aﬀect
the anesthetic eﬀects of bupivacaine.
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